Your browser doesn't support javascript.
loading
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance.
Thatikonda, Venu; Lu, Hengyu; Jurado, Sabine; Kostyrko, Kaja; Bristow, Christopher A; Bosch, Karin; Feng, Ningping; Gao, Sisi; Gerlach, Daniel; Gmachl, Michael; Lieb, Simone; Jeschko, Astrid; Machado, Annette A; Marszalek, Ethan D; Mahendra, Mikhila; Jaeger, Philipp A; Sorokin, Alexey; Strauss, Sandra; Trapani, Francesca; Kopetz, Scott; Vellano, Christopher P; Petronczki, Mark; Kraut, Norbert; Heffernan, Timothy P; Marszalek, Joseph R; Pearson, Mark; Waizenegger, Irene; Hofmann, Marco H.
  • Thatikonda V; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Lu H; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jurado S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Kostyrko K; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Bristow CA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bosch K; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gao S; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gerlach D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Gmachl M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Lieb S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Jeschko A; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Machado AA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Marszalek ED; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mahendra M; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jaeger PA; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Sorokin A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Strauss S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Trapani F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vellano CP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Petronczki M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Kraut N; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Heffernan TP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Marszalek JR; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pearson M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Waizenegger I; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  • Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
bioRxiv ; 2023 Jan 23.
Article en En | MEDLINE | ID: mdl-36747713
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2023 Tipo del documento: Article